Popular Searches

MitoRiboSeq / Mitochondrial Ribosome Profiling Service — Codon-Level Mitochondrial Translation Dynamics

Quantify mitochondrial translation at single-codon resolution. Identify mitoribosome stalling, drug-induced translation defects, and OXPHOS-specific translation profiles.

MitoRiboSeq captures mitoribosome-protected footprints from the mitochondrial genome, enabling codon-resolution analysis of the 13 OXPHOS subunit translation products. Our workflow combines mitoribosome enrichment, footprint library preparation, and a specialized mitochondrial bioinformatics pipeline.

  • Codon-level resolution: A-site occupancy, stalling sites, codon bias analysis
  • Mitoribosome-specific enrichment via sucrose gradient separation
  • Specialized pipeline: mtDNA alignment, A-site assignment, codon count tables
  • Multi-omics integration: RNA-seq, proteomics, OXPHOS functional readouts
Discuss Your Mitochondrial Translation Study
MitoRiboSeq mitochondrial ribosome profiling service
OverviewApplicationsWorkflowSamplesBioinformaticsComparisonDemoCaseFAQ

Why MitoRiboSeq — Mitochondrial Translation at Codon Resolution

Mitochondrial translation produces 13 essential OXPHOS subunits encoded by mtDNA. Mitoribosomes have distinct sedimentation properties: the 55S mitoribosome elutes between cytosolic 40S and 60S subunits during gradient fractionation. Standard RNA-seq or Ribo-seq cannot resolve mitoribosome-specific translation because mitoribosome footprints are shorter (25-35 nt) and co-migrate with cytosolic components. Our standard Ribo-seq service captures total ribosome footprints, which are >95% cytosolic.

MitoRiboSeq overcomes this by dedicated 5-45% sucrose gradient separation that resolves 55S mitoribosomes from 40S/60S/80S cytosolic components, followed by size-selected footprint library preparation targeting 25-35 nt fragments, and mitochondrial-specific bioinformatics using the revised Cambridge Reference Sequence (rCRS) for alignment. Our team has adapted the published Nature Protocols workflow to accommodate multiple cell types, drug treatment conditions, and patient-derived fibroblast lines — each with sample-specific optimization of lysis conditions, nuclease digestion parameters, and gradient fractionation windows.

The method enables: (i) A-site codon counts for all 22 sense codons and 3 stop codons used by the mitochondrial genome; (ii) codon occupancy analysis normalized to genomic codon frequency to identify stalling sites; (iii) gene-level translation efficiency profiles across all 13 mitochondrial ORFs (ND1-6, ND4L, COX1-3, ATP6, ATP8, CYTB); and (iv) differential translation analysis between conditions with biological replicate-based statistics. We provide complete documentation of every QC gate, from footprint size distribution to replicate reproducibility, so that each published result is defensible.

Our expertise: The MitoRiboSeq pipeline requires specialized experience in mitoribosome enrichment that differs substantially from standard Ribo-seq. Key challenges we have addressed include: minimizing cytosolic ribosome carryover during fraction collection, optimizing MNase digestion time to avoid over-digestion of the fragile mitoribosome, validating A-site assignment using codon periodicity metrics, and normalizing mtDNA copy number variation across samples through parallel qPCR or mtDNA sequencing. Our scientists have hands-on experience with each of these optimization steps, and we apply this knowledge to every new project.

Applications in Mitochondrial Disease, Drug Toxicity and Mechanism Research

Mitochondrial Disease Mechanisms

Mutations in mt-tRNA genes (MT-TL1 responsible for MELAS, MT-TK for MERRF, MT-TI, MT-TN) impair mitochondrial translation by directly affecting tRNA charging efficiency or codon-anticodon recognition. MitoRiboSeq directly identifies which specific codons show reduced mitoribosome occupancy in patient-derived cells, revealing translation stalling as a molecular pathomechanism. For example, the m.3243A>G MT-TL1 mutation reduces decoding of UUR leucine codons, while m.8344A>G MT-TK impairs AAA and AAG lysine decoding. This codon-resolution diagnostic information is not obtainable from RNA-seq, proteomics, or standard Ribo-seq. We work with academic collaborators to process fibroblast lines, cybrid models, and differentiated neurons from patient cohorts under RUO compliance.

Drug-Induced Mitochondrial Toxicity

Many drug classes produce off-target mitoribosome inhibition: certain antibiotic classes and other small-molecule compounds. These compounds bind the 55S mitoribosome large subunit and inhibit peptidyl transferase activity, leading to condition-dependent OXPHOS dysfunction. MitoRiboSeq identifies which of the 13 mitochondrial ORFs are most affected, at which codons stalling occurs, and whether translation inhibition is uniform or transcript-specific. This application is directly relevant for preclinical safety assessment, lead optimization, and mechanistic toxicology studies in pharmaceutical R&D. Our team can design multi-dose time-course experiments to establish dose-response relationships between drug concentration, codon-level stalling, and downstream OXPHOS activity.

Cancer Metabolism and OXPHOS Remodeling

Cancer cells rewire their metabolism through OXPHOS modulation, with specific translational regulation of complex I (ND1-6) and complex IV (COX1-3) subunits. MitoRiboSeq reveals which OXPHOS subunits are translationally regulated under metabolic stress, hypoxia, or upon treatment with mitochondrial-targeted therapies (mitochondrial complex inhibitors). Published work has established that SHMT2 knockout in HCT116 cells causes mitoribosome stalling at AAG (lysine) and UUG (leucine) codons, directly linking one-carbon metabolism to mitochondrial translation fidelity. Our service enables identification of such metabolic-translational coupling in any cell model of interest.

Aging, Neurodegeneration and Metabolic Disorders

Mitochondrial translation efficiency declines with age in multiple tissues, and mitoribosome dysfunction is increasingly implicated in Parkinson disease (PINK1/Parkin pathway), Alzheimer disease (mitochondrial dynamics), and metabolic disorders (obesity, type 2 diabetes, non-alcoholic steatohepatitis). MitoRiboSeq enables profiling of age- or disease-related changes in OXPHOS translation across tissues, cell models, and organoids, providing mechanistic insight into the contribution of mitochondrial translation dysfunction to disease pathogenesis. We routinely process primary fibroblasts, iPSC-derived neurons, hepatocyte models, and cardiac tissue samples for academic and translational research teams. For broader ribosome loading analysis, our polysome profiling service provides global translation state information across monosome and polysome fractions.

Our publication track record: We have supported mitochondrial translation projects published in peer-reviewed journals covering mitochondrial disease, cancer metabolism, and drug mechanism studies. Each project includes a data review session with our bioinformatics scientists to ensure that codon-level findings are correctly interpreted in their biological context.

Service Workflow: From Mitoribosome Enrichment to Codon Occupancy

  1. Sample lysis and nuclease digestion (QC gate 1). Cells are lysed in polysome extraction buffer containing RNase inhibitors, Mg2+, and protease inhibitors. Lysates are treated with micrococcal nuclease (MNase) at optimized concentration and time to digest unprotected RNA while preserving mitoribosome-protected fragments. QC: We monitor digestion efficiency by agarose gel electrophoresis and adjust MNase units per sample batch.
  2. Mitoribosome enrichment via sucrose gradient (QC gate 2). Digested lysates are loaded onto 5-45% linear sucrose gradients prepared in gradient buffer and ultracentrifuged at 35,000 rpm for 3 h at 4°C using a SW41 Ti rotor. Gradients are fractionated with continuous UV monitoring at 254 nm. The 55S mitoribosome fraction is collected as the material eluting between the 40S and 60S cytosolic subunit peaks. QC: The UV trace is reviewed for proper 40S/60S/80S separation and the absence of aggregate peaks.
  3. RNA extraction and size selection (QC gate 3). RNA is extracted from the pooled mitoribosome fraction using TRIzol LS. RNA is resolved on a 15% denaturing PAGE gel, and the 25-35 nt footprint region is excised. QC: Size distribution is verified by Bioanalyzer High Sensitivity RNA assay before proceeding to library preparation.
  4. Footprint library preparation (QC gate 4). 3-prime end repair (T4 PNK), 3-prime adapter ligation, reverse transcription using adapter-specific primer, ssDNA circularization (CircLigase), and PCR amplification with indexing primers. QC: Library size distribution is assessed on Bioanalyzer High Sensitivity DNA chip. Expected final library size: 157-187 bp.
  5. High-throughput sequencing. Libraries are pooled and sequenced on Illumina NovaSeq 6000 (single-end 75 bp or paired-end 150 bp). Minimum 30 million reads per sample recommended for mitoribosome footprint analysis.
  6. Specialized bioinformatics pipeline (QC gate 5). Reads are adapter-trimmed (cutadapt), quality-filtered (FastQC), aligned to rCRS mtDNA (Bowtie2), and filtered for mapping quality (MAPQ ≥ 20). A-site assignment is performed by offset calculation from aligned fragment 5-prime ends. Codon count tables are generated per mitochondrial gene, and codon occupancy scores are computed. QC: Codon periodicity is checked to validate A-site assignment accuracy. Only samples with >80% of reads in frame pass this gate.

MitoRiboSeq workflow: enrichment to codon occupancy

Sample Requirements and Quality Control

Parameter Requirement Notes
Cell number ≥ 2 × 107 per condition Multiple 15 cm dishes needed
Cell state Log-phase growth Confluent cells show reduced translation
Biological replicates ≥ 3 per condition Mitochondrial data noisier than cytosolic
CHX treatment Not required CHX does not inhibit mitoribosomes
Shipping Dry ice, Mon-Wed Flash-frozen cell pellets preferred

Our QC deliverables: Every project includes a comprehensive QC report with the following pass/fail metrics, each benchmarked against published MitoRiboSeq data from the Nature Protocols reference: (1) Footprint size distribution — expected peak at 25-35 nt; (2) Mitochondrial read fraction — expected ≥5% of total aligned reads mapping to mtDNA (% varies by tissue and mitoribosome enrichment efficiency); (3) rRNA contamination — expected <30% of reads aligning to mitochondrial rRNA (12S and 16S); (4) Biological replicate correlation — expected Pearson R ≥ 0.8 for codon counts; (5) Gene body coverage — all 13 ORFs must have ≥5 reads per base median coverage; (6) Codon periodicity — A-site assignment validation by 3-nt periodicity test. Samples that fail any metric are flagged and discussed with the client before proceeding to downstream analysis. This rigorous QC framework ensures data quality is documented at every step, providing the defensibility required for publication.

Bioinformatics Analysis and Deliverables

Deliverable Description Format
Raw sequencing data Demultiplexed FASTQ with per-base quality scores FASTQ
Aligned footprints Reads aligned to rCRS mtDNA, MAPQ ≥ 20 filtered, A-site assigned BAM
Codon count table Counts per A-site per codon per mitochondrial gene per replicate CSV
Codon occupancy analysis Occupancy scores per codon type; stalling sites identified by >2-fold enrichment over genomic average; p-values from replicate comparison CSV + PDF
Gene-level translation profile Normalized footprint density per ORF; start/stop coverage; cumulative counts plots for individual transcripts (e.g., MT-ATP6, MT-COX1) CSV + PDF
Differential analysis Codon- and gene-level comparison across conditions: fold-change, p-value, FDR. Parallel coordinate plot of condition-specific stalling patterns. CSV + PDF
QC report Footprint size distribution, mtDNA fraction, rRNA level, replicate correlation, gene body coverage, codon periodicity. All metrics compared to Nature Protocols benchmark. PDF
Multi-omics add-on Integrated RNA-seq + MitoRiboSeq comparison: transcriptional vs. translational regulation of OXPHOS genes. Optional proteomics (mitochondrial fraction) or Seahorse functional correlation. Report

Analysis pipeline details: We use a Snakemake-based workflow adapted from the published MitoRiboSeq pipeline (Li et al. 2021, GitHub: sophiahjli/MitoRiboSeq). This includes: adapter trimming (cutadapt), rRNA filtering (Bowtie2 against rRNA reference), mtDNA alignment (Bowtie2 to rCRS), A-site assignment with periodicity validation, codon count aggregation, and downstream R-based statistical analysis. All pipeline versions are recorded for reproducibility.

MitoRiboSeq vs Standard Ribo-seq vs RNA-seq

Method Measures Resolution Mitochondrial Specific Key Limitation
MitoRiboSeq Mitoribosome footprints Codon-level (3 nt) Yes — dedicated 55S enrichment via gradient Requires ≥2×10^7 cells; specialized bioinformatics
Standard Ribo-seq Total ribosome footprints (>95% cytosolic) Codon-level (3 nt) No — <5% mitochondrial without enrichment Cannot resolve mitoribosome-specific translation
Mitochondrial RNA-seq mtRNA abundance (polyA+ or total) Transcript-level Yes — mtRNA present Measures transcription, not translation; no stalling info
Proteomics (mito fraction) Mitochondrial protein abundance Protein-level Yes — requires mito isolation No codon or stalling resolution; higher cost

Standard Ribo-seq is not a substitute for MitoRiboSeq. Over 95% of footprints originate from cytosolic ribosomes. Dedicated mitoribosome enrichment is essential for meaningful mitochondrial translation analysis. For a complete overview of translation profiling methods, visit our translatomics sequencing services page.

Demo Results — Representative MitoRiboSeq Data

- Codon occupancy heatmap (Fig. A): Hierarchical clustering of A-site codon counts across all biological replicates and conditions. Each row represents one of the 25 mitochondrial codons, organized by decreasing frequency in the mitochondrial genome. Color scale: blue (low occupancy) to red (high occupancy/stalling). Stalling sites identified as outliers with >2-fold enrichment relative to the genomic average appear as consistently red clusters in the KO or treated condition. This visualization immediately reveals which codons are affected by the perturbation and whether the effect is consistent across replicates.

- Gene-level translation profile (Fig. B): Cumulative mitoribosome footprint density plotted along the length of each of the 13 mitochondrial ORFs individually. For each transcript, we show: the normalized read count per nucleotide position, start and stop codon annotation, positions of each codon type, and a smoothed rolling average (50-nt window) to highlight regions of elevated or reduced translation. Individual codons with significantly elevated footprint density are flagged as candidate stalling sites with p-values from replicate analysis.

- Differential stalling analysis (Fig. C): Codon-by-codon comparison of occupancy scores between two conditions (e.g., treated vs. untreated, KO vs. WT, mutant vs. control). Results are displayed as: (i) a scatter plot comparing codon occupancy between conditions with identity line; (ii) a bar chart showing fold-change per codon with significance asterisks; (iii) a parallel coordinate plot tracing individual codon behavior across multiple conditions. Key output: prioritized list of codons with statistically significant occupancy changes, ranked by effect size and consistency.

MitoRiboSeq codon occupancy heatmap clusteringCodon occupancy heatmap (WT vs SHMT2 KO pattern).

MitoRiboSeq gene-level translation profile MT-ATP6Cumulative footprints along MT-ATP6.

MitoRiboSeq differential codon stalling analysisDifferential codon occupancy comparison.

Case Study — SHMT2 Knockout and Mitoribosome Stalling at Specific Codons

Li et al. investigated whether defects in mitochondrial serine catabolism affect mitoribosome translation fidelity. SHMT2 (serine hydroxymethyltransferase 2) catalyzes serine-to-glycine conversion, producing one-carbon units for mitochondrial tRNA methylation. They hypothesized that SHMT2 loss impairs tRNA modification and causes mitoribosome stalling at specific codons.

MitoRiboSeq was performed on HCT116 wild-type (WT) and SHMT2 knockout (KO) cells. Cells were lysed, MNase-digested, and subjected to 5-45% sucrose gradient ultracentrifugation for mitoribosome enrichment. Libraries from 25-35 nt footprints were sequenced. Bioinformatics generated codon count tables for all 25 mitochondrial codons (n=2-3 replicates per condition). Full protocol: Li et al. Nature Protocols 2021.

SHMT2 KO cells showed mitoribosome stalling at AAG and UUG codons ( Fig. 7a-b). Clustering of codon counts (Fig. 7a) separated WT and KO replicates. Codon occupancy (Fig. 7b) identified AAG and UUG as stalling sites in KO cells (red). Cumulative counts along MT-ATP6 (Fig. 7c) showed elevated footprint density at AAG/UUG positions. Fraction of codon counts along MT-ATP6 (Fig. 7d) confirmed stalling patterns. Source: Li et al. Nature Protocols 2021, Fig. 7a-d (CC BY 4.0).

SHMT2 KO MitoRiboSeq Fig 7 codon occupancy and stalling

This study demonstrates that MitoRiboSeq is uniquely capable of identifying codon-specific mitoribosome stalling caused by metabolic perturbations — information that cannot be obtained from RNA-seq, proteomics, or any other single-omics approach. The SHMT2 KO model directly links one-carbon metabolism to mitochondrial translation fidelity at specific codons, illustrating the mechanistic depth achievable with this technology.

Why this matters for your project: If you have a hypothesis about mitochondrial translation regulation — whether driven by a genetic mutation, drug treatment, metabolic stress, or disease state — MitoRiboSeq provides the direct, codon-resolution evidence needed to test it. Our team has hands-on experience with the full workflow from sample preparation through data interpretation. We invite you to discuss your specific research question with our scientists to determine whether MitoRiboSeq — or a combination with our other translatome profiling services — is the right approach for your study.

Frequently Asked Questions

References

  1. Li SHJ, Nofal M, Parsons LR, Rabinowitz JD, Gitai Z. Monitoring mammalian mitochondrial translation with MitoRiboSeq. Nature Protocols. 2021;16(7):3337-3367. doi:10.1038/s41596-021-00517-1
  2. Rooijers K, Loayza-Puch F, Nijtmans LG, Agami R. Ribosome profiling reveals features of normal and disease-associated mitochondrial translation. Nature Communications. 2013;4:2886. doi:10.1038/ncomms3886
  3. Pearce SF, Capitanio C, Goto T, et al. Mitoribosome profiling from human cell lines: a re-engineered approach. Methods in Molecular Biology. 2023;2661:245-263. doi:10.1007/978-1-0716-3171-3_15
  4. Su D, Ding C, Qiu J, et al. Ribosome profiling: a powerful tool in oncological research. Biomarker Research. 2024;12:11. doi:10.1186/s40364-024-00562-4

*This service is for research use only (RUO). Results are intended for exploratory and mechanistic research applications and are not intended for clinical diagnosis, treatment selection, patient stratification, or therapeutic decision-making.



  • Related Resources
Related Resources
Ribo-tRNA

Learn More
Related Resources
Polysome profiling+proteomics

Learn More
Related Resources
Polysome profiling+IncRNA-seq

Learn More
Related Resources
OmniRNA-seq

Learn More
Inquiry
  • For research purposes only, not intended for clinical diagnosis, treatment, or individual health assessments.
RNA
Popular Services
Research Areas
Copyright © CD Genomics. All rights reserved.
Top
Get a Quote
×
Quote Request
  • For research purposes only, not intended for clinical diagnosis, treatment, or individual health assessments.